about
Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors[Haemolytic uremic syndrome and acute mesenteric ischemia caused by interferon-alpha-2b in the treatment of Kaposi's sarcoma in an AIDS patient].Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinomaFirst-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanomaPhenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia.Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk.Mixed nonseminomatous germ cell tumor presenting as a subcutaneous tissue mass.The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanomaFetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy.Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?Therapy of advanced squamous cell carcinoma of the skin.A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variantsManagement of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines.A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.[Panniculitis induced by interferon beta-1a vascular toxicity]Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma.[Chloroquine cardiotoxicity in long-term lupus therapy in two patients].French ENT Society (SFORL) guidelines for the management of immunodeficient patients with head and neck cancer of cutaneous origin.Common skin cancers in porokeratosis.Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France.[Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides].[Melanoma in HIV patients: 14 cases].Management and outcome of metastatic melanoma during pregnancy.Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families.Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma.Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients.Minocycline-induced DRESS: evidence for accumulation of the culprit drug.Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit.Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism.Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.Characteristics of the coexistence of melanoma and renal cell carcinoma.[Kimura's disease associated with extracapillary glomerulonephritis]High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome.[Metastatic extraskeletal osteosarcoma revealed by an occipital mass].[Acute generalized exanthematous pustulosis induced by phloroglucinol].
P50
Q27350034-364E2416-F176-4DC2-BE87-9AD3D2F3E324Q33374679-39D6C64D-86A1-4530-B8BF-D7413267D184Q33701787-7E461A8B-2307-44A1-A017-DC343AB37F54Q34524746-20211CE1-4380-4091-8903-33252EB7BD9BQ35034899-AB895C84-098A-4330-876B-6FD527979C0FQ35719855-938E4EE0-7831-4FC1-A84E-A9E2EB29A137Q35963112-03362ABF-1FCF-48B9-9893-09F7571087A8Q36051433-1AD0851C-18D7-4A2E-9FF7-D3213C2773F4Q36661358-23C90A8B-FAC4-40F8-9EB5-D0615AC8180EQ36785968-E50B25AC-FA80-46DD-9B3A-E8D5E4AC772CQ37071912-EB6F5D66-5ED8-4604-99AA-B42D4326DD52Q37222127-40197D49-9F09-436E-B917-90482EC73EF9Q37635306-0594E8FE-6A22-4E37-A740-DD0B6709AEDEQ38197119-990A9878-5319-499D-983D-95E6A5542A65Q38445526-814D6A4E-9E18-4B00-A74B-9FE7479D39A9Q38572591-B0A30D44-4CAA-401D-992E-57FFD4EA056CQ39455824-0196FD0C-D4C4-499F-A6F2-8379D71C6412Q40450695-1BCA98EC-B980-4FCA-9250-18849E87867FQ40546307-90786D90-43D4-4CAD-8BAD-7008CC54721DQ40698804-C3E7A00D-EEB9-4B1E-AEC6-8A5A70CA8D01Q40897816-779E2A1C-65D9-438C-B8CC-D9A395BBD3F4Q41938083-C95D09F9-20D1-4083-A867-279EA2EAC72DQ42229773-503CE385-FB8C-46A4-A6ED-97F612BDC448Q42479680-1F52296B-4E1E-4112-94D3-5B3FAD591979Q42509906-7133060D-0C29-4370-840E-EBE9A47F85EDQ43241131-2633A84A-F60E-4797-A12F-5847C432F590Q44496674-BA51D50A-3FD1-4664-85EF-84397CB21629Q45166883-16231D68-33A9-4F77-BAB9-50A439E862BAQ45194373-6C07FDA1-75A0-4526-B010-E4A2A8A965F9Q45807165-37E1C122-06A6-4619-A451-B7F92D75AB15Q46002119-47438598-91B1-4C59-8348-74E8C5A80AB8Q46817118-79787840-C126-4C0F-9317-AA6E47CD4712Q48312483-FA1BDB9A-0025-49D4-8330-753ADFC773B1Q50205519-83B6BE62-75FB-4E53-A686-51592B8EB153Q50492928-52880247-9C0E-41E4-85DF-F4DE3949EAC8Q50549151-5DAE4EEF-39B6-4EC7-A80E-993A205F5FBEQ50850206-EC948D5B-CE73-4EFB-B112-EB1E8E6F13ADQ52717489-B85D34FB-22B7-4DD2-8765-B752375F0A6CQ53406172-DD7D13F4-D406-4046-BC50-1BFA7B84D53AQ53475916-E12CE121-815C-4E40-AAF6-F1010643085C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eve Maubec
@ast
Eve Maubec
@en
Eve Maubec
@es
Eve Maubec
@nl
Eve Maubec
@sl
type
label
Eve Maubec
@ast
Eve Maubec
@en
Eve Maubec
@es
Eve Maubec
@nl
Eve Maubec
@sl
altLabel
Eve Corda
@en
prefLabel
Eve Maubec
@ast
Eve Maubec
@en
Eve Maubec
@es
Eve Maubec
@nl
Eve Maubec
@sl
P1053
V-4296-2017
P106
P31
P496
0000-0003-1658-6686